We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kerry Group Plc | LSE:KYGA | London | Ordinary Share | IE0004906560 | 'A'ORD EUR0.125 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.00 | 2.50% | 82.10 | 78.40 | 79.70 | 80.90 | 79.10 | 80.90 | 116,083 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Food Preparations, Nec | 8.02B | 728.3M | 4.1150 | 19.34 | 14.09B |
TIDMKYGA
RNS Number : 5387E
Kerry Group PLC
08 July 2021
Date: 8 July 2021
LEI: 635400TLVVBNXLFHWC59
KERRY GROUP
Kerry Group plc announces the result of its public tender offer for Biosearch Life
Kerry Group plc ("Kerry"), the global taste & nutrition company, hereby announces the successful result of its public tender offer through its Spanish subsidiary Kerry Iberia Taste & Nutrition, S.L.U on Biosearch, S.A. ("Biosearch"). Following expiry of the acceptance period on June 29th, 52,121,923 Biosearch shares were tendered into the offer, representing 90.33% of the share capital of Biosearch. The result of the offer was approved by the Spanish National Securities Markets Commission on July 5th, 2021 and the acquisition of the shares tendered will be settled today July 8(th) , 2021.
As anticipated in the offer document and given all necessary conditions are met, Kerry will compulsorily acquire all the remaining shares of Biosearch which have not yet been tendered. The compensation paid will be equal to the price of the tender offer, i.e. EUR2.20 per share. The total consideration for the transaction is EUR126.9m.
Biosearch is a leading biotechnology company focused on providing innovative solutions for the pharmaceutical, nutraceutical and functional food sectors. Based in Granada, Spain, the company provides an extensive range of probiotics with leadership in premium probiotics obtained from human breast milk (Hereditum(R) brand), scientifically backed innovative botanical extracts (Exxentia(R)) and natural omega-3 (Eupoly-3(R) brand).
Edmond Scanlon, CEO of Kerry, commented: We have significantly advanced our capabilities in proactive nutrition in recent years. Biosearch is a strong complement to our portfolio and brings leading clinical research capabilities and functional food technologies across multiple life stages and need states. We share a commitment to advance the science behind healthier food and I would like to extend a warm welcome to the Biosearch team."
ENDS
About Kerry Group
Kerry is the world's leading taste and nutrition partner for the food, beverage and pharmaceutical industries. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,000+ food scientists and local manufacturing footprint in 31 countries enable us to co-create with our customers across over 150 countries. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and will reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerrygroup.com .
About Biosearch Life
Biosearch Life is a leading biotechnology company providing innovative solutions worldwide in the pharmaceutical, nutraceutical and functional food sectors with a workforce of over 150 employees. Biosearch distributes its products across Europe, Asia and the USA and had revenue of EUR25.3m in 2020. It provides a wide range of high-quality products and services which revolve around the concept of a healthy life with products in three primary areas: probiotics, botanical extracts, and omega-3 fatty acids.
CONTACT INFORMATION ============================================= Investor Relations Marguerite Larkin , Chief Financial Officer +353 66 7182292 | investorrelations@kerry.ie William Lynch , Head of Investor Relations +353 66 7182292 | investorrelations@kerry.ie Media Catherine Keogh , Chief Corporate Affairs & Brand Officer +353 45 930188 | corpaffairs@kerry.com Website www.kerrygroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACQFLFLTDSIDIIL
(END) Dow Jones Newswires
July 08, 2021 02:00 ET (06:00 GMT)
1 Year Kerry Chart |
1 Month Kerry Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions